Search Results

Aspen Neuroscience announced that it is partnering with Emerald Innovations, a pioneer in the creation of “invisible” off-body sensors for measuring health analytics, and Rune Labs, a software and data analytics company for precision neurology, to incorporate digital health modalities in the company’s Trial-Ready Screening Cohort Study.

Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has concluded the merger transaction with Emerald Health Therapeutics (“Emerald”). Both companies’ shareholders voted in favor of the transaction and the Supreme Court of British Columbia approved the transaction.

Verge Genomics announced that Emerald Innovations’ wireless digital health technology will be used to capture critical patient data in its planned Phase 1b proof-of-concept study of the PIKfyve inhibitor VRG50635, a novel therapeutic in clinical development for amyotrophic lateral sclerosis (ALS).

Emerald Health Pharmaceuticals Inc. has received a positive safety review following a pre-specified interim analysis by the Safety Review Committee (“SRC”) of its Phase 2a study of EHP-101 for systemic sclerosis (“SSc”).

BlueRock Therapeutics LP today announced a collaboration with Rune Labs and Emerald Innovations focused on using wearable and invisible contactless digital health technology to improve monitoring and data collection for Parkinson’s disease clinical trials.

IMFINZI ® (durvalumab) plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolization in EMERALD-1 Phase III trial.

Corvus Pharmaceuticals, Inc. today announced that Richard A. Miller, M.D., president and chief executive officer, and Jeffrey Arcara, chief business officer, will conduct one-on-one meetings with investors and present a corporate overview at the Jefferies Global Health Conference, which is being held in New York from June 5-7, 2024.

Xenon Pharmaceuticals Inc. announced that the company will present at the BofA Securities Health Care Conference 2024 taking place May 14-16, 2024 in Las Vegas, NV.

Corbus Pharmaceuticals Holdings, Inc. today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a panel discussion as part of the BTIG Obesity Health Forum, to be held virtually on May 8, 2024.